NewsVandana Singh
Alterity Therapeutics
ATHE · ASX
$2.09−$0.06 (−2.79%)TodayMarket closed ·
Prev close $2.15
Latest news
- Press releaseGlobe Newswire
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- Press releaseGlobe Newswire
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
- Press releaseGlobe Newswire
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
- Press releaseGlobe Newswire
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
- Press releaseGlobe Newswire
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
- NewsVandana Singh
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
- Press releaseGlobe Newswire
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
- Press releaseGlobe Newswire
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- Press releaseGlobe Newswire
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
Nasdaq Moves Lower; Meta Platforms Posts Strong Sales
- NewsDylan Berman
What's Going On With Alterity Therapeutics Shares Thursday?
- NewsAvi Kapoor
Dow Jumps Over 100 Points; Tesla Earnings Miss Views
- Press releaseGlobe Newswire
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.